North Korea has rejected around three million doses of a Chinese COVID-19 vaccine, suggesting they should be given to countries in greater need, UNICEF said on Thursday.

The impoverished North was the first country to impose a strict lockdown when it sealed its border in January last year to stop the virus spreading from neighbouring China, where it first emerged before sweeping the world.

Pyongyang insists it has yet to see any cases of the virus — a claim that analysts doubt — but it has paid a huge economic price for the blockade, with the regime admitting in June it was tackling a “food crisis”.

Regardless, the isolated country told UNICEF — which distributes vaccines under the COVID-19 Vaccine Global Access (Covax) programme for low-income countries — that the Chinese-made vaccines could be given to others, the UN agency said.

North Korea’s public health ministry “has communicated that the 2.97 million Sinovac doses being offered to DPR Korea by Covax may be relocated to severely affected countries in view of the limited global supply of COVID-19 vaccines and recurrent surge in some countries”, a UNICEF spokesperson told AFP.

Pyongyang would “continue to communicate” with COVAX “to receive COVID-19 vaccines in the coming months”, they added.

In July, a South Korean think tank affiliated with Seoul’s spy agency said Pyongyang had also rejected shipments of AstraZeneca’s vaccine offered by the COVAX scheme, apparently over concerns about side effects.

The Institute for National Security Strategy added at the time that the North was not equipped with sufficient cold chain storage for the Pfizer and Moderna vaccines, while being sceptical about the effectiveness of Chinese vaccines.

— AFP

Subscribe
Notify of
6 Comments
Newest
Oldest Most Voted
Inline Feedbacks
View all comments
You May Also Like

60 new cases of COVID-19 infection in S’pore; 56 locally transmitted cases, 41 belong to KTV cluster

As of Wednesday noon (14 July), the Ministry of Health (MOH) has…

Cheap diabetes drug reduces risk of long COVID: study

A study conducted in the United States found that taking the diabetes drug metformin after testing positive for COVID-19 reduced the risk of developing long COVID by 40 per cent. The trial involved over 1,100 overweight or obese participants, with half receiving metformin and half receiving a placebo. The findings were considered significant in the fight against long COVID, a condition that affects approximately one in 10 individuals who have had COVID-19.

Biden expands blacklist of Chinese firms off-limits to US investors

US President Joe Biden on Thursday expanded a blacklist of Chinese firms…

‘Strange atmosphere’: Disappointed athletes brace for crowd-free Tokyo Games

The joy has gone for French decathlete Kevin Mayer, while Australian tennis…